Details of the Drug

General Information of Drug (ID: DM4ME02)

Drug Name

Ticarcillin

Synonyms

TIPC; Ticarcilina; Ticarcilline; Ticarcillinum; Ticarcillin Supplement; Ticillin [veterinary]; BRL-2288; Ticarcilina[INN-Spanish]; Ticarcillin (INN); Ticarcillin [INN:BAN]; Ticarcilline [INN-French]; Ticarcillinum [INN-Latin]; Ticillin [veterinary] (TN); Timentin (TN); A-carboxy-3-thienylmethylpenicillin; Alpha-carboxy-3-thienylmethylpenicillin; (2S,5R,6R)-6-[[(2R)-3-hydroxy-3-oxo-2-thiophen-3-ylpropanoyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-carboxy-2-(3-thienyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6beta-{[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino}-2,2-dimethylpenam-3alpha-carboxylic acid

Indication

Disease Entry	ICD 11	Status	REF
Aspiration pneumonia	N.A.	Approved	[1]
Bacteremia	1A73	Approved	[1]
Bacterial infection	1A00-1C4Z	Approved	[2]
Lung abscess	N.A.	Approved	[1]
Pleural empyema	N.A.	Approved	[1]
Salpingitis	N.A.	Approved	[1]
Staphylococcal pneumonia	N.A.	Approved	[1]
Staphylococcus aureus infection	N.A.	Approved	[1]
Urinary tract infection	GC08	Approved	[1]
Pelvic inflammatory disease	GA05	Investigative	[1]


⏷ Show the Full List of Indication(s)

Therapeutic Class

Antibiotics

Affected Organisms

Enteric bacteria and other eubacteria

ATC Code

J01CA13: Ticarcillin

J01CA: Penicillins with extended spectrum

J01C: BETA-LACTAM ANTIBACTERIALS, PENICILLINS

J01: ANTIBACTERIALS FOR SYSTEMIC USE

J: ANTIINFECTIVES FOR SYSTEMIC USE

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

384.4

Logarithm of the Partition Coefficient (xlogp)

0.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Clearance: The drug present in the plasma can be removed from the body at the rate of 1.8 mL/min/kg [4]
Elimination: 77% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 1.1 hours [4]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 780.37091 micromolar/kg/day [5]
Unbound Fraction: The unbound fraction of drug in plasma is 0.55% [4]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.16 L/kg [4]
Water Solubility: The ability of drug to dissolve in water is measured as 1000 mg/mL [3]

Chemical Identifiers

Formula: C15H16N2O6S2
IUPAC Name: (2S,5R,6R)-6-[[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
Canonical SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CSC=C3)C(=O)O)C(=O)O)C
InChI: InChI=1S/C15H16N2O6S2/c1-15(2)9(14(22)23)17-11(19)8(12(17)25-15)16-10(18)7(13(20)21)6-3-4-24-5-6/h3-5,7-9,12H,1-2H3,(H,16,18)(H,20,21)(H,22,23)/t7-,8-,9+,12-/m1/s1
InChIKey: OHKOGUYZJXTSFX-KZFFXBSXSA-N

Cross-matching ID

PubChem CID: 36921
ChEBI ID: CHEMBL9587
CAS Number: 34787-01-4
UNII: F93UJX4SWT
DrugBank ID: DB01607
TTD ID: D08USU
INTEDE ID: DR2409

Drug Pharmacogenomic Perturbation (DPP)^NEW

Click to Jump to the Detailed DPP Information of This Drug

Drug ADMET Endpoint Profile (DAE)^NEW

Click to Jump to the Detailed DAE Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Penicillin binding protein (Bact PBP)	TTJP4SM	NOUNIPROTAC	Binder	[6]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Beta-lactamase (blaB)	DED0TBR	A0A414M273_9BACE	Substrate	[7]
Beta-lactamase (blaB)	DERGEVU	C3WC84_FUSMR	Substrate	[7]
Beta-lactamase (blaB)	DEQMISO	F9Z530_ODOSD	Substrate	[7]
Beta-lactamase (blaB)	DEHFJ4G	Q8KT51_9BACT	Substrate	[7]
Beta-lactamase (blaB)	DEHPJRC	Q8KT60_9BACT	Substrate	[7]
Beta-lactamase (blaB)	DE37FJH	C6JIU1_FUSVA	Substrate	[8]
Beta-lactamase (blaB)	DEF01WC	A0A3S4HKA9_CHRVL	Substrate	[9]

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Ticarcillin FDA Label
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 050497.
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Activities of antibiotics against methicillin-resistant Staphylococcus aureus with particular reference to synergetic effect between ticarcillin and fosfomycin on penicillinase non-producing methicillin-resistant S. aureus. Jpn J Antibiot. 1993 Jun;46(6):421-7.
7	Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin. Antimicrob Agents Chemother. 1994 Feb;38(2):211-6.
8	Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers. Antimicrob Agents Chemother. 1990 Aug;34(8):1546-50.
9	Beta-lactamase activity in Chromobacterium violaceum. J Infect Dis. 1976 Sep;134(3):290-3.